Previous 10 | Next 10 |
2024-05-22 17:08:12 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics CEO Blum says positioned to marke...
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced t...
SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten a...
2024-05-20 14:41:36 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips On the search for high-quality stocks at low prices? Consider taking a look at dividend stocks at a 52-week low. Sure, at first, you may find it to be a red flag that a particular stock is ...
2024-05-11 11:40:20 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-05-11 06:23:38 ET Summary Royalty Pharma reports Q1 earnings with a 14% growth in portfolio receipts and net cash from operating activities at $665 million. The company continues to acquire royalties, including Sanofi's potential blockbuster drug Frexalimab. Royalty Pharm...
2024-05-09 13:32:02 ET Royalty Pharma PLC (RPRX) Q1 2024 Earnings Conference Call May 9, 2024 08:00 ET Company Participants George Grofik - Senior Vice President & Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman & Chief Exe...
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million Net cash provided by operating activities of $665 million Full year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 million Commitment to grow dividend by mid-single d...
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases Expands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater tha...
2024-05-08 14:17:12 ET More on Royalty Pharma Royalty Pharma: Solid Operational Performance Royalty Pharma PLC (RPRX) Q4 2023 Earnings Call Transcript Royalty Pharma plc 2023 Q4 - Results - Earnings Call Presentation Teva, Medincell succeed in late-stage tria...
News, Short Squeeze, Breakout and More Instantly...